Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

Yi Lin; Lugui Qiu; Saad Usmani; Chng Wee Joo; Luciano Costa; Benjamin Derman; Juan Du; Hermann Einsele; Carlos Fernandez de Larrea; Roman Hajek; P Joy Ho; Efstathios Kastritis; Joaquin Martinez-Lopez; Maria-Victoria Mateos; Joseph Mikhael; Philippe Moreau; Chandramouli Nagarajan; Ajay Nooka; Michael O'Dwyer; Fredrik Schjesvold; Surbhi Sidana; Niels Wcj van de Donk; Katja Weisel; Sonja Zweegman; Noopur Raje; Paula Rodriguez Otero; Larry D Anderson; Shaji Kumar; Tom Martin; International Myeloma Working Group

doi:10.1016/S1470-2045(24)00094-9

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

Standard

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. / Lin, Yi; Qiu, Lugui; Usmani, Saad; Joo, Chng Wee; Costa, Luciano; Derman, Benjamin; Du, Juan; Einsele, Hermann; Fernandez de Larrea, Carlos; Hajek, Roman; Ho, P Joy; Kastritis, Efstathios; Martinez-Lopez, Joaquin; Mateos, Maria-Victoria; Mikhael, Joseph; Moreau, Philippe; Nagarajan, Chandramouli; Nooka, Ajay; O'Dwyer, Michael; Schjesvold, Fredrik; Sidana, Surbhi; van de Donk, Niels Wcj; Weisel, Katja; Zweegman, Sonja; Raje, Noopur; Otero, Paula Rodriguez; Anderson, Larry D; Kumar, Shaji; Martin, Tom; International Myeloma Working Group.

In: LANCET ONCOL, Vol. 25, No. 8, 08.2024, p. e374-e387.

Research output: SCORING: Contribution to journal › Guideline, recommendation, statement › Research › peer-review

Harvard

Lin, Y, Qiu, L, Usmani, S, Joo, CW, Costa, L, Derman, B, Du, J, Einsele, H, Fernandez de Larrea, C, Hajek, R, Ho, PJ, Kastritis, E, Martinez-Lopez, J, Mateos, M-V, Mikhael, J, Moreau, P, Nagarajan, C, Nooka, A, O'Dwyer, M, Schjesvold, F, Sidana, S, van de Donk, NW, Weisel, K, Zweegman, S, Raje, N, Otero, PR, Anderson, LD, Kumar, S, Martin, T & International Myeloma Working Group 2024, 'Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee', LANCET ONCOL, vol. 25, no. 8, pp. e374-e387. https://doi.org/10.1016/S1470-2045(24)00094-9

APA

Lin, Y., Qiu, L., Usmani, S., Joo, C. W., Costa, L., Derman, B., Du, J., Einsele, H., Fernandez de Larrea, C., Hajek, R., Ho, P. J., Kastritis, E., Martinez-Lopez, J., Mateos, M-V., Mikhael, J., Moreau, P., Nagarajan, C., Nooka, A., O'Dwyer, M., ... International Myeloma Working Group (2024). Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. LANCET ONCOL, 25(8), e374-e387. https://doi.org/10.1016/S1470-2045(24)00094-9

Vancouver

Lin Y, Qiu L, Usmani S, Joo CW, Costa L, Derman B et al. Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee. LANCET ONCOL. 2024 Aug;25(8):e374-e387. https://doi.org/10.1016/S1470-2045(24)00094-9

Bibtex

@article{855ee00f5d0c4a7981a35a3a5a88c345,

title = "Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee",

abstract = "Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.",

author = "Yi Lin and Lugui Qiu and Saad Usmani and Joo, {Chng Wee} and Luciano Costa and Benjamin Derman and Juan Du and Hermann Einsele and {Fernandez de Larrea}, Carlos and Roman Hajek and Ho, {P Joy} and Efstathios Kastritis and Joaquin Martinez-Lopez and Maria-Victoria Mateos and Joseph Mikhael and Philippe Moreau and Chandramouli Nagarajan and Ajay Nooka and Michael O'Dwyer and Fredrik Schjesvold and Surbhi Sidana and {van de Donk}, {Niels Wcj} and Katja Weisel and Sonja Zweegman and Noopur Raje and Otero, {Paula Rodriguez} and Anderson, {Larry D} and Shaji Kumar and Tom Martin and {International Myeloma Working Group}",

year = "2024",

month = aug,

doi = "10.1016/S1470-2045(24)00094-9",

language = "English",

volume = "25",

pages = "e374--e387",

journal = "LANCET ONCOL",

issn = "1470-2045",

publisher = "Lancet Publishing Group",

number = "8",

}

RIS

TY - JOUR

T1 - Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

AU - Lin, Yi

AU - Qiu, Lugui

AU - Usmani, Saad

AU - Joo, Chng Wee

AU - Costa, Luciano

AU - Derman, Benjamin

AU - Du, Juan

AU - Einsele, Hermann

AU - Fernandez de Larrea, Carlos

AU - Hajek, Roman

AU - Ho, P Joy

AU - Kastritis, Efstathios

AU - Martinez-Lopez, Joaquin

AU - Mateos, Maria-Victoria

AU - Mikhael, Joseph

AU - Moreau, Philippe

AU - Nagarajan, Chandramouli

AU - Nooka, Ajay

AU - O'Dwyer, Michael

AU - Schjesvold, Fredrik

AU - Sidana, Surbhi

AU - van de Donk, Niels Wcj

AU - Weisel, Katja

AU - Zweegman, Sonja

AU - Raje, Noopur

AU - Otero, Paula Rodriguez

AU - Anderson, Larry D

AU - Kumar, Shaji

AU - Martin, Tom

AU - International Myeloma Working Group

PY - 2024/8

Y1 - 2024/8

N2 - Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.

AB - Chimeric antigen receptor (CAR) T-cell therapy has shown promise in patients with late-line refractory multiple myeloma, with response rates ranging from 73 to 98%. To date, three products have been approved: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), which are approved by the US Food and Drug Administration, the European Medicines Agency, Health Canada (ide-cel only), and Brazil ANVISA (cilta-cel only); and equecabtagene autoleucel (eque-cel), which was approved by the Chinese National Medical Products Administration. CAR T-cell therapy is different from previous anti-myeloma therapeutics with unique toxic effects that require distinct mitigation strategies. Thus, a panel of experts from the International Myeloma Working Group was assembled to provide guidance for clinical use of CAR T-cell therapy in myeloma. This consensus opinion is from experts in the field of haematopoietic cell transplantation, cell therapy, and multiple myeloma therapeutics.

U2 - 10.1016/S1470-2045(24)00094-9

DO - 10.1016/S1470-2045(24)00094-9

M3 - Guideline, recommendation, statement

C2 - 38821074

VL - 25

SP - e374-e387

JO - LANCET ONCOL

JF - LANCET ONCOL

SN - 1470-2045

IS - 8

ER -